{
    "nct_id": "NCT04040088",
    "official_title": "Utility of Gallium-68-DOTA-Octreotate PET/CT in the Characterization of Pediatric Neuroendocrine Tumors",
    "inclusion_criteria": "* Age =< 30 years\n* Histological confirmation of neuroblastoma, ganglioneuroblastoma, or ganglioneuroma.\n* High-risk neuroblastoma requiring consolidative RT, as determined by the treating radiation oncologist.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3 (patients 16 years old or older at entry) or Lansky Score of 30-100 (patients <16 years old at entry).\n* Planned for radiation planning and RT at enrolling institution.\n* Documented negative pregnancy test prior to induction chemotherapy, for women of childbearing age within =< 7 days prior to registration.\n* Willing to return to enrolling institution for follow-up imaging and clinical evaluation, or willing to send follow-up imaging and clinical notes to enrolling institution (during the observation phase of the study).\nHealthy volunteers allowed\nMust have maximum age of 30 Years",
    "exclusion_criteria": "* Pregnant women, nursing women who refuse to stop breastfeeding, or men/women of childbearing age who are unwilling to use an effective birth control method.\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.\n* Immunocompromised patients and patients known to be human immunodeficiency virus positive and currently receiving antiretroviral therapy. NOTE: Patients known to be human immunodeficiency virus positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.",
    "miscellaneous_criteria": ""
}